Skip to main content

Month: February 2024

Shell plc Fourth Quarter 2023 Interim Dividend

London, February 1, 2024 − The Board of Shell plc (the “Company”) today announced an interim dividend in respect of the fourth quarter of 2023 of US$ 0.344 per ordinary share. Details relating to the fourth quarter 2023 interim dividendPer ordinary share Q4 2023Shell Shares (US$) 0.344Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros. Absent any valid election to the contrary, shareholders (both holding in certificated and uncertificated form (CREST members)) and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling. The pound sterling and euro equivalent dividend...

Continue reading

Cabka 2023 preliminary update

Amsterdam, Feb. 01, 2024 (GLOBE NEWSWIRE) — Amsterdam February 1, 2024. Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, announced its 2023 preliminary update today. The last quarter of 2023 showed a significant 35% Quarter-on-Quarter recovery in sales to €53 million (Q3 2023: €40 million). Total sales for the full year of 2023 amounted to €197 million, 6% lower compared to the record sales achieved in 2022 of €209 million. Total 2023 sales ended €3 million below outlook, fully attributable to an agreed delayed new customer project launch. Consequently, this caused a 0.8% negative impact on the operational EBITDA margin for full year 2023.   The company expects...

Continue reading

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Genflow Biosciences Plc (“Genflow” or “the Company”) LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) — The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024. The Company achieved many significant accomplishments throughout the year across all aspects of its business. The full year-end review can be viewed on Genflow’s website: https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/. Key 2023 Highlights:Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.Began...

Continue reading

Michael Austwick Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings a wealth of strategic and operational experience in the biopharmaceutical industry including more than 15 years of respiratory expertise in leadership roles across the US, China, Europe and Japan. Most recently, he served as CEO at Vectura, and previously as Nordic General Manager and Head of the Global Respiratory Franchise at Novartis and as Head of US Respiratory and Vice President Global Inhaled Respiratory at AstraZeneca. Mr. Austwick has led the development and commercialization of more than 10 brands, covering inhaled and biologic assets at a country and global level. He has an MSc in Information Management...

Continue reading

Results update for 2023 – unaudited

6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to be released on February 8, this announcement only contains unaudited numbers. Full audited financial statements as well as non-financial numbers will be released with the annual report on February 8. This result update allows us to provide selected numbers for Novozymes standalone as early as possible. Ester Baiget, President & CEO: “I am very pleased with our performance in 2023 – a year characterized by changing market demand and inventory adjustments in certain industries. The strength of Novozymes’ diversified portfolio and end-market exposure enables us to capture growth opportunities as they arise, providing...

Continue reading

Compagnie Financiere Tradition: Adjusted revenue of CHF 1,053.9m in 2023, up 9.5%

  Ad hoc announcement pursuant to Article 53 of the Six ExchangeRegulation Listing Rules    Lausanne, 1 February 2024 Adjusted1) revenue of CHF 1,053.9m in 2023,up 9.5% at constant exchange rates;Growth of 11.5% in the 4th quarter at constant exchange rates Compagnie Financière Tradition recorded a growth in its reported revenue (IFRS) for the full 2023 financial year and in particular in the 4th quarter with an increase of 10.6% and 13.4% respectively at constant exchange rates. Indeed, the normalization of the monetary policy of central banks with the increase in interest rates during the year followed by an observation period in the search of the balance point that combine the control of inflation and a soft landing of the economy, all in an already complex geopolitical...

Continue reading

Prosafe SE: Fourth quarter 2023 results

EBITDA for the fourth quarter was USD (2.7) million (USD 9.6 million). The decrease in EBITDA was mainly driven by lower utilisation, including Eurus SPS off hire, and higher operating expenses during the quarter compared to 2022. Prosafe sees increased vessel demand going forward, which is expected to lead to higher utilisation, improved day rates and earnings growth. Executive summary(Figures in brackets refer to the corresponding period last year) Market and outlookFour out of six options declared for Safe Concordia taking firm period through 09 November 2024 Favourable outlook with Prosafe controlling a significant share of open high-end accommodation capacity from 2024 to 2026 Strong and improving Brazil market with rising day rates and durations on the back of increased demand. Further long and short-term contracts expected North...

Continue reading

ING posts 4Q2023 net result of €1,558 million and full-year 2023 net result of €7,287 million

ING posts 4Q2023 net result of €1,558 million and full-year 2023 net result of €7,287 million  Quarterly profit before tax increases 31% year-on-year to €2,247 million; CET1 ratio remains strong at 14.7%• Income up 11% year-on-year and net interest income holds up well in the quarter• Increase of 236,000 primary retail customers in the fourth quarter, combined with stable deposits and growth in lending• Low risk costs, reflecting strong asset quality and disciplined risk management Full-year result before tax of €10,492 million, with strong contributions from both Retail and Wholesale Banking• Exceptional results in a year that was characterised by a rapid increase of interest rates and a benign economic environment• Retail Banking results supported by growth in primary customers, customer...

Continue reading

Dassault Systèmes Doubles EPS as Planned in 2018 While Embracing The Subscription Model

Press Release VELIZY-VILLACOUBLAY, France — February 1st, 2024 Dassault Systèmes Doubles EPS as Planned in 2018 While Embracing The Subscription Model Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), today announced IFRS unaudited estimated financial results for the fourth quarter and fiscal year ended December 31, 2023. The Group’s Board of Directors approved these estimated results on January 31, 2024. This press release includes financial information on a non-IFRS basis and reconciliations with IFRS figures in the Appendix. Summary Highlights    (unaudited, IFRS and non-IFRS unless otherwise noted,all revenue growth rates in constant currencies)4Q23 & FY23 total revenue increased 8% and 9% respectively with software revenue up 8%, all in line with objectives; 4Q23 & FY23 recurring revenue rose 12% and 10% respectively,...

Continue reading

BMW Group Partners with Dassault Systèmes to Bring the 3DEXPERIENCE Platform to Its Future Engineering Platform

 Strategic partnership will develop BMW Group’s future engineering platform with Dassault Systèmes’ 3DEXPERIENCE platform at its core 17,000 users will be working globally on a virtual twin of a vehicle that can be configured for the variants of each model with consistent data in real timePartnership marks next step in the history of collaboration between the two companies that has influenced automotive industrial innovation for decadesVELIZY-VILLACOUBLAY, France and MUNICH — February 1, 2024 — Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and BMW Group today embarked on a long-term strategic partnership to develop BMW Group’s future engineering platform featuring Dassault Systèmes’ 3DEXPERIENCE platform at its core.   More than 17,000 employees across multiple engineering disciplines at the premium automobile manufacturer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.